Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Novan, Inc. (Nasdaq: NOVN) announced that Paula Brown Stafford, CEO, will participate in a panel titled, “Distraction or Destruction?: What’s New/Next in the Industry,” at the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference on December 8, 2022, at 11:00 AM ET. The discussion will cover innovative therapies in medical and aesthetic dermatology, upcoming milestones, and challenges within the industry. Additionally, management will hold one-on-one meetings with registered investors at the event.
Novan focuses on developing therapies for unmet medical needs, including SB206 for viral skin infections.
Details
News Market Reaction – NOVN
The recorded move for NOVN in the trading session of this news was +20.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
– Paula Brown Stafford, President and Chief Executive Officer of Novan to participate in a live moderated panel discussion on Thursday, December 8th at 11:00 AM ET –
DURHAM, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will participate in a panel discussion titled, “Distraction or Destruction?: What’s New/Next in the Industry,” at the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference on Thursday, December 8, 2022 at 11:00 AM ET.
The panel discussion will highlight medical and aesthetic dermatology companies and their innovative platform therapies and provide opportunity to discuss upcoming milestones and anticipated findings from data in the next 12-18 months. Additionally, participants will discuss the unmet needs and challenges across various areas, including those that currently have no approved therapies and how their therapies fit into the current treatment paradigm to address those needs.
In addition to the panel presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
The panel discussion is open to those who are registered to attend the event. Please contact your Cantor representative for more information.
About Novan
Novan, Inc. is a medical dermatology company primarily focused on researching, developing, and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. We are developing SB206 (berdazimer gel,
Novan completed the acquisition of EPI Health in early 2022. EPI Health equips the company with a robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams. Following the acquisition, the company employs approximately 100 staff, including sales personnel currently covering 42 territories, and promotes products for plaque psoriasis, rosacea, acne and dermatoses. Novan also has a pipeline of potential product candidates using our proprietary nitric oxide-based technology platform, NITRICIL™, to generate new treatments for multiple indications.
INVESTOR AND MEDIA CONTACT:
Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.